Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2000 Mar;59(3):196–205. doi: 10.1136/ard.59.3.196

Blockade of endogenous interleukin 12 results in suppression of murine streptococcal cell wall arthritis by enhancement of interleukin 10 and interleukin 1Ra

L Joosten 1, M Helsen 1, W B van den Berg 1
PMCID: PMC1753084  PMID: 10700428

Abstract

OBJECTIVE—The goal of this study was to investigate the role of endogenous interleukin 12 (IL12) in acute murine streptococcal cell wall (SCW) arthritis.
METHODS—C57black/6 mice were injected intraperitoneally with rat anti-murine IL12 (C17.8), shortly before induction of arthritis by intra-articular injection of 25 µg SCW fragments into the right knee joint. Joint swelling and chondrocyte synthetic function was analysed several days after induction of SCW arthritis. Local cytokine profile was determined, protein by using ELISA and mRNA by RT-PCR technology. To confirm the findings at later time points, tissue chamber model of inflammation was used. Histology was performed to examine cell influx and cartilage damage.
RESULTS—Suppression of joint swelling was noted at days 2 and 4, whereas no suppressive effect of anti-IL12 was found at day 1. Severe inhibition of chondrocyte proteoglycan synthesis was seen at day 1 in both arthritic control and anti-IL12 treated mice. However, chondrocyte function was restored at day 4 of arthritis in the anti-IL12 injected animals, but not in the arthritic controls. Moreover, cell influx in synovial tissue and joint cavity was reduced by anti-IL12 treatment. Neutralisation of IL12 reduced the local levels of IL1β, IL12 and interferon γ, when examined shortly after induction of SCW arthritis, whereas tumour necrosis factor α levels were not affected. In contrast, IL10 and IL1Ra protein and mRNA levels were strongly up regulated in synovial tissues after IL12 blockade. Enhancement of IL10 and IL1Ra by anti-IL12 was confirmed in a tissue chamber model with SCW induced inflammation.
CONCLUSIONS—This study indicates that IL12 is a pro-inflammatory cytokine during onset of acute SCW arthritis. Balances of proinflammatory and anti-inflammatory cytokines were strongly improved by anti-IL12 treatment.



Full Text

The Full Text of this article is available as a PDF (292.3 KB).

Figure 1  .

Figure 1  

Open in a new tab

SCW arthritis, joint swelling, chondrocyte proteoglycan (PG) synthesis, and cytokine profile. (A) SCW arthritis was induced by injection of 25 µg SCW fragments. Joint swelling was measured by 99mTc uptake method and is expressed as right/left ratio. A ratio >1.10 is considered as inflammation. Inhibition of chondrocyte PG synthesis was determined by 35S-sulphate incorporation. The data represent the mean (SD) of at least seven mice per group. (B) Cytokine levels were determined either by RIA or ELISA in patellae washouts at several time points. The data represent the mean cytokine level of washouts of six patellae per time point.

Figure 2  .

Figure 2  

Open in a new tab

Effect of anti-IL12 treatment on joint swelling and chondrocyte PG synthesis. (A) Mice were given an intraperitoneal injection two hours before induction of arthritis with either 0.5 mg rat anti-murine IL12 or rat Igs. At days 1, 2, and 4 joint swelling was determined by 99mTC uptake and expressed as R/L ratio. The data represent the mean (SD) of at least seven mice per group. (B) Chondrocyte PG synthesis was measured by 35S-sulphate incorporation at days 1, 2, and 4 after induction of arthritis. The data represent mean (SD) percentage chondrocyte PG synthesis of the left control patella. *p<0.05, Mann-Whitney U test, compared with rat Igs group.

Figure 3  .

Figure 3  

Open in a new tab

Effect of IL12 blockade on cell influx and cartilage damage in the knee joint. (A) Arthritic nee joint of the rat Igs treated control group. Note the marked joint inflammation and cell influx in the joint cavity. Bar=80 µM. (B) Section of the control group stained for matrix proteoglycan. Note the loss of matrix PG in the cartilage layers (arrows). Bar=40 µM. (C) Knee joint of a mouse treated with anti-IL12 antibodies. Strong reduction of cell influx can be seen in synovial tissue and joint cavity. Bar=80 µM. (D) Section of anti-IL12 treated knee joint stained for PG loss. No reduction of matrix PG depletion was seen after IL12 blockade. Bar=40 µM. p= patella, f= femur, c= cartilage, js= joint space, s= synovium. (A and C) Haematoxilin and eosin staining, (B and D) safranin O staining. All specimens were taken at day 2 after induction of SCW arthritis.    

Figure 4  .

Figure 4  

Open in a new tab

Kinetics of IL12 neutralisation on joint swelling and chondrocyte PG synthesis. (A) Mice were treated intraperitoneally with anti-IL12 at either −2 hours, day 1 or day 2 after induction of SCW arthritis. As control we injected at the same time points rat Igs. Joint swelling was determined at day 3. The data represent the mean (SD) joint swelling of at least seven mice per group. (B) Chondrocyte PG synthesis measured at day 4. Mice were treated with either anti-IL12 or rat Igs as indicated above. The data are expressed as mean (SD) percentage of chondrocyte PG synthesis found in left control patella of at least seven patellae per group. *p< 0.05, Mann-Whitney U test, compared with rat Igs.

Figure 5  .

Figure 5  

Open in a new tab

Synovial cytokine concentrations after IL12 neutralisation. Mice were given an intraperitoneal injection with either anti-IL12 or rat Igs before induction of arthritis. After either 90 minutes (TNFα) or four hours (all other cytokines), patellae were isolated and cytokine levels were determined in washouts. A, TNFα and IL1β. (B) IFNγ and IL12. C, IL10 and IL1Ra. The data represent mean (SD) cytokine level in at least six patellae washouts. *p<0.05, Mann-Whitney U test, compared with rat Igs group.

Figure 6  .

Figure 6  

Open in a new tab

RT-PCR analysis of synovial tissue mRNA levels for TNFα (A), IL1β (B), IFNγ (C), IL12 (D), IL10 (E), IL1Ra (F) after intraperitoneal treatment with either anti-IL12 or rat Igs. Synovium biopsy specimens of six mice per group were pooled and RNA was extracted. Expressed is the number of PCR cycles in which gene product of interest was first detectable compared with normal synovium. Values are the mean of two experiments with SCW arthritis. The cycle curves were done by two cycle intervals. The PCR measurements of a particular cytokine was routinely repeated three times. The variations never exceeded more than two cycles. The absolute difference in mRNA levels were calculated using the difference in PCR cycles between arthritic synovium and non-inflamed synovium (two cycles mean 22 more mRNA, four cycles = 24). From these values ratios for IL1Ra/IL1β (G) and IL10/TNFα (H) were calculated, using delta PCR cycles found in F/B and E/A.

Figure 7  .

Figure 7  

Open in a new tab

PCR analysis of synovial tissue at days 1 and 2 after anti-IL12 treatment. Synovial biopsy specimens of six mice per experimental group were pooled, and RNA was extracted. PCR was performed as described in Methods. Animals were injected intraperitoneally with either 0.5 mg rat Igs (I) or rat anti-murine IL12 (II) before induction of SCW arthritis. Note the reduced IFNγ and IL12 and the increased IL1Ra and IL10 levels at day 2. † The number of PCR cycles.

Figure 8  .

Figure 8  

Open in a new tab

Effect of anti-IL12 treatment on cytokine levels in tissue-chamber model. Tissue-chambers were implanted subcutaneously seven days before injection intraperitoneally of either anti-IL12 or rat Igs. Two hours later, 100 µl SCW fragments were injected. At days 1 and 2 200 µl tissue-chamber fluid was extracted. Levels of TNFα (A), IL1β (B), IFNγ (C), IL12 (D), IL10 (E) and IL1Ra (F) were determined by RIA or ELISA. The data are expressed as mean (SD) cytokine level of six tissue-chambers per group. *p<0.05, Mann-Whitney U test, compared with rat Igs.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbas A. K., Murphy K. M., Sher A. Functional diversity of helper T lymphocytes. Nature. 1996 Oct 31;383(6603):787–793. doi: 10.1038/383787a0. [DOI] [PubMed] [Google Scholar]
  2. Arend W. P., Dayer J. M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum. 1995 Feb;38(2):151–160. doi: 10.1002/art.1780380202. [DOI] [PubMed] [Google Scholar]
  3. Boissier M. C., Chiocchia G., Bessis N., Hajnal J., Garotta G., Nicoletti F., Fournier C. Biphasic effect of interferon-gamma in murine collagen-induced arthritis. Eur J Immunol. 1995 May;25(5):1184–1190. doi: 10.1002/eji.1830250508. [DOI] [PubMed] [Google Scholar]
  4. Chen E., Keystone E. C., Fish E. N. Restricted cytokine expression in rheumatoid arthritis. Arthritis Rheum. 1993 Jul;36(7):901–910. doi: 10.1002/art.1780360706. [DOI] [PubMed] [Google Scholar]
  5. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  6. Cope A. P., Sønderstrup G. Evaluating candidate autoantigens in rheumatoid arthritis. Springer Semin Immunopathol. 1998;20(1-2):23–39. doi: 10.1007/BF00831997. [DOI] [PubMed] [Google Scholar]
  7. Cromartie W. J., Craddock J. G., Schwab J. H., Anderle S. K., Yang C. H. Arthritis in rats after systemic injection of streptococcal cells or cell walls. J Exp Med. 1977 Dec 1;146(6):1585–1602. doi: 10.1084/jem.146.6.1585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. D'Andrea A., Rengaraju M., Valiante N. M., Chehimi J., Kubin M., Aste M., Chan S. H., Kobayashi M., Young D., Nickbarg E. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med. 1992 Nov 1;176(5):1387–1398. doi: 10.1084/jem.176.5.1387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dodge G. R., Diaz A., Sanz-Rodriguez C., Reginato A. M., Jimenez S. A. Effects of interferon-gamma and tumor necrosis factor alpha on the expression of the genes encoding aggrecan, biglycan, and decorin core proteins in cultured human chondrocytes. Arthritis Rheum. 1998 Feb;41(2):274–283. doi: 10.1002/1529-0131(199802)41:2<274::AID-ART11>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
  10. Drenth J. P., Van Uum S. H., Van Deuren M., Pesman G. J., Van der Ven-Jongekrijg J., Van der Meer J. W. Endurance run increases circulating IL-6 and IL-1ra but downregulates ex vivo TNF-alpha and IL-1 beta production. J Appl Physiol (1985) 1995 Nov;79(5):1497–1503. doi: 10.1152/jappl.1995.79.5.1497. [DOI] [PubMed] [Google Scholar]
  11. Gazzinelli R. T., Hieny S., Wynn T. A., Wolf S., Sher A. Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6115–6119. doi: 10.1073/pnas.90.13.6115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hodge-Dufour J., Noble P. W., Horton M. R., Bao C., Wysoka M., Burdick M. D., Strieter R. M., Trinchieri G., Puré E. Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resident but not elicited macrophages. J Immunol. 1997 Sep 1;159(5):2492–2500. [PubMed] [Google Scholar]
  13. Huang F. P., Feng G. J., Lindop G., Stott D. I., Liew F. Y. The role of interleukin 12 and nitric oxide in the development of spontaneous autoimmune disease in MRL/MP-lpr/lpr mice. J Exp Med. 1996 Apr 1;183(4):1447–1459. doi: 10.1084/jem.183.4.1447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Joosten L. A., Helsen M. M., van de Loo F. A., van den Berg W. B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum. 1996 May;39(5):797–809. doi: 10.1002/art.1780390513. [DOI] [PubMed] [Google Scholar]
  15. Joosten L. A., Lubberts E., Helsen M. M., van den Berg W. B. Dual role of IL-12 in early and late stages of murine collagen type II arthritis. J Immunol. 1997 Oct 15;159(8):4094–4102. [PubMed] [Google Scholar]
  16. Kanangat S., Blair P., Reddy R., Daheshia M., Godfrey V., Rouse B. T., Wilkinson E., Deheshia M. Disease in the scurfy (sf) mouse is associated with overexpression of cytokine genes. Eur J Immunol. 1996 Jan;26(1):161–165. doi: 10.1002/eji.1830260125. [DOI] [PubMed] [Google Scholar]
  17. Kobayashi M., Fitz L., Ryan M., Hewick R. M., Clark S. C., Chan S., Loudon R., Sherman F., Perussia B., Trinchieri G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989 Sep 1;170(3):827–845. doi: 10.1084/jem.170.3.827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kruijsen M. W., van den Berg W. B., van de Putte L. B., van den Broek W. J. Detection and quantification of experimental joint inflammation in mice by measurement of 99mTc-pertechnetate uptake. Agents Actions. 1981 Dec;11(6-7):640–642. doi: 10.1007/BF01978775. [DOI] [PubMed] [Google Scholar]
  19. Kuiper S., Joosten L. A., Bendele A. M., Edwards C. K., 3rd, Arntz O. J., Helsen M. M., Van de Loo F. A., Van den Berg W. B. Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine. 1998 Sep;10(9):690–702. doi: 10.1006/cyto.1998.0372. [DOI] [PubMed] [Google Scholar]
  20. Lawrence C., Nauciel C. Production of interleukin-12 by murine macrophages in response to bacterial peptidoglycan. Infect Immun. 1998 Oct;66(10):4947–4949. doi: 10.1080/00222936700770321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Leonard J. P., Waldburger K. E., Goldman S. J. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med. 1995 Jan 1;181(1):381–386. doi: 10.1084/jem.181.1.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lubberts E., Joosten L. A., Helsen M. M., van den Berg W. B. Regulatory role of interleukin 10 in joint inflammation and cartilage destruction in murine streptococcal cell wall (SCW) arthritis. More therapeutic benefit with IL-4/IL-10 combination therapy than with IL-10 treatment alone. Cytokine. 1998 May;10(5):361–369. doi: 10.1006/cyto.1997.0298. [DOI] [PubMed] [Google Scholar]
  23. Magram J., Connaughton S. E., Warrier R. R., Carvajal D. M., Wu C. Y., Ferrante J., Stewart C., Sarmiento U., Faherty D. A., Gately M. K. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity. 1996 May;4(5):471–481. doi: 10.1016/s1074-7613(00)80413-6. [DOI] [PubMed] [Google Scholar]
  24. Matthys P., Vermeire K., Mitera T., Heremans H., Huang S., Billiau A. Anti-IL-12 antibody prevents the development and progression of collagen-induced arthritis in IFN-gamma receptor-deficient mice. Eur J Immunol. 1998 Jul;28(7):2143–2151. doi: 10.1002/(SICI)1521-4141(199807)28:07<2143::AID-IMMU2143>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  25. Mattner F., Magram J., Ferrante J., Launois P., Di Padova K., Behin R., Gately M. K., Louis J. A., Alber G. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol. 1996 Jul;26(7):1553–1559. doi: 10.1002/eji.1830260722. [DOI] [PubMed] [Google Scholar]
  26. Morita Y., Yamamura M., Nishida K., Harada S., Okamoto H., Inoue H., Ohmoto Y., Modlin R. L., Makino H. Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis Rheum. 1998 Feb;41(2):306–314. doi: 10.1002/1529-0131(199802)41:2<306::AID-ART15>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
  27. Neurath M. F., Fuss I., Kelsall B. L., Stüber E., Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995 Nov 1;182(5):1281–1290. doi: 10.1084/jem.182.5.1281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Oluyomi A. O., Nguyen H., Towbin H., Dawson J., Vosbeck K. Differential effects of prednisolone and indomethacin on zymosan-induced inflammation in a modified murine tissue-chamber model. Inflamm Res. 1995 Aug;44(8):350–356. doi: 10.1007/BF01796267. [DOI] [PubMed] [Google Scholar]
  29. Ozmen L., Pericin M., Hakimi J., Chizzonite R. A., Wysocka M., Trinchieri G., Gately M., Garotta G. Interleukin 12, interferon gamma, and tumor necrosis factor alpha are the key cytokines of the generalized Shwartzman reaction. J Exp Med. 1994 Sep 1;180(3):907–915. doi: 10.1084/jem.180.3.907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Palmer R. M., Hickery M. S., Charles I. G., Moncada S., Bayliss M. T. Induction of nitric oxide synthase in human chondrocytes. Biochem Biophys Res Commun. 1993 May 28;193(1):398–405. doi: 10.1006/bbrc.1993.1637. [DOI] [PubMed] [Google Scholar]
  31. Parks E., Strieter R. M., Lukacs N. W., Gauldie J., Hitt M., Graham F. L., Kunkel S. L. Transient gene transfer of IL-12 regulates chemokine expression and disease severity in experimental arthritis. J Immunol. 1998 May 1;160(9):4615–4619. [PubMed] [Google Scholar]
  32. Rao K. L., Varalakshmi C., Ali A. M., Khar A. Administration of anti-IL-12 antibody in vivo inhibits rejection of a rat histiocytoma and suppresses cytokine response in a tumour-bearing host. Immunology. 1997 Nov;92(3):381–387. doi: 10.1046/j.1365-2567.1997.00362.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Sakurai H., Kohsaka H., Liu M. F., Higashiyama H., Hirata Y., Kanno K., Saito I., Miyasaka N. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest. 1995 Nov;96(5):2357–2363. doi: 10.1172/JCI118292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Schrier D. J., Schimmer R. C., Flory C. M., Tung D. K., Ward P. A. Role of chemokines and cytokines in a reactivation model of arthritis in rats induced by injection with streptococcal cell walls. J Leukoc Biol. 1998 Mar;63(3):359–363. doi: 10.1002/jlb.63.3.359. [DOI] [PubMed] [Google Scholar]
  35. Seder R. A., Gazzinelli R., Sher A., Paul W. E. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10188–10192. doi: 10.1073/pnas.90.21.10188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Segal B. M., Shevach E. M. IL-12 unmasks latent autoimmune disease in resistant mice. J Exp Med. 1996 Aug 1;184(2):771–775. doi: 10.1084/jem.184.2.771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Seitz M., Loetscher P., Dewald B., Towbin H., Baggiolini M. Opposite effects of interleukin-13 and interleukin-12 on the release of inflammatory cytokines, cytokine inhibitors and prostaglandin E from synovial fibroblasts and blood mononuclear cells. Eur J Immunol. 1996 Sep;26(9):2198–2202. doi: 10.1002/eji.1830260935. [DOI] [PubMed] [Google Scholar]
  38. Stern A. S., Podlaski F. J., Hulmes J. D., Pan Y. C., Quinn P. M., Wolitzky A. G., Familletti P. C., Stremlo D. L., Truitt T., Chizzonite R. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6808–6812. doi: 10.1073/pnas.87.17.6808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Taskiran D., Stefanovic-Racic M., Georgescu H., Evans C. Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem Biophys Res Commun. 1994 Apr 15;200(1):142–148. doi: 10.1006/bbrc.1994.1426. [DOI] [PubMed] [Google Scholar]
  40. Trembleau S., Penna G., Bosi E., Mortara A., Gately M. K., Adorini L. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med. 1995 Feb 1;181(2):817–821. doi: 10.1084/jem.181.2.817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Trinchieri G. Immunobiology of interleukin-12. Immunol Res. 1998;17(1-2):269–278. doi: 10.1007/BF02786451. [DOI] [PubMed] [Google Scholar]
  42. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol. 1995;13:251–276. doi: 10.1146/annurev.iy.13.040195.001343. [DOI] [PubMed] [Google Scholar]
  43. Van Meurs J. B., Van Lent P. L., Joosten L. A., Van der Kraan P. M., Van den Berg W. B. Quantification of mRNA levels in joint capsule and articular cartilage of the murine knee joint by RT-PCR: kinetics of stromelysin and IL-1 mRNA levels during arthritis. Rheumatol Int. 1997;16(5):197–205. doi: 10.1007/BF01330296. [DOI] [PubMed] [Google Scholar]
  44. Walmsley M., Katsikis P. D., Abney E., Parry S., Williams R. O., Maini R. N., Feldmann M. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum. 1996 Mar;39(3):495–503. doi: 10.1002/art.1780390318. [DOI] [PubMed] [Google Scholar]
  45. Willems F., Marchant A., Delville J. P., Gérard C., Delvaux A., Velu T., de Boer M., Goldman M. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol. 1994 Apr;24(4):1007–1009. doi: 10.1002/eji.1830240435. [DOI] [PubMed] [Google Scholar]
  46. Williams R. O., Feldmann M., Maini R. N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9784–9788. doi: 10.1073/pnas.89.20.9784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Wysocka M., Kubin M., Vieira L. Q., Ozmen L., Garotta G., Scott P., Trinchieri G. Interleukin-12 is required for interferon-gamma production and lethality in lipopolysaccharide-induced shock in mice. Eur J Immunol. 1995 Mar;25(3):672–676. doi: 10.1002/eji.1830250307. [DOI] [PubMed] [Google Scholar]
  48. van de Loo F. A., Arntz O. J., van Enckevort F. H., van Lent P. L., van den Berg W. B. Reduced cartilage proteoglycan loss during zymosan-induced gonarthritis in NOS2-deficient mice and in anti-interleukin-1-treated wild-type mice with unabated joint inflammation. Arthritis Rheum. 1998 Apr;41(4):634–646. doi: 10.1002/1529-0131(199804)41:4<634::AID-ART10>3.0.CO;2-1. [DOI] [PubMed] [Google Scholar]
  49. van de Loo F. A., Joosten L. A., van Lent P. L., Arntz O. J., van den Berg W. B. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum. 1995 Feb;38(2):164–172. doi: 10.1002/art.1780380204. [DOI] [PubMed] [Google Scholar]
  50. van den Broek M. F., van den Berg W. B., van de Putte L. B., Severijnen A. J. Streptococcal cell wall-induced arthritis and flare-up reaction in mice induced by homologous or heterologous cell walls. Am J Pathol. 1988 Oct;133(1):139–149. [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES